GRCE
Grace Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.10
−1.87%Aug 13, 2026, 12:00 UTC
Grace Therapeutics announced its financial results for the first quarter of fiscal 2027 (three months ended June 30, 2026).
Source:Aug 5, 2026, 01:00 UTC
Grace Therapeutics announced a $10 million private placement, with expected gross proceeds anticipated to extend the company's cash runway to the end of calendar 2028.
Source:Jul 28, 2026, 11:00 UTC
Grace Therapeutics received Type A meeting minutes from the U.S. Food and Drug Administration regarding a Complete Response Letter for GTx-104.
Source:Jun 18, 2026, 00:00 UTC
Grace Therapeutics, Inc. reported a net loss of $7.8 million and diluted loss per share of $0.47 for fiscal year 2026.
Jun 5, 2026, 00:00 UTC
Carrie D'Andrea departed as Vice President of Clinical Operations of Grace Therapeutics, Inc. effective June 5, 2026.
Jun 3, 2026, 19:54 UTC
The FDA issued a Complete Response Letter to Grace Therapeutics regarding its New Drug Application for GTx-104, citing deficiencies in leachables data, non-clinical toxicology risk assessments, and product manufacturing at its contract manufacturing organization.
Source: